Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaginal intraepithelial neoplasia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Vaginal intraepithelial neoplasia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-007763-16 Sponsor Protocol Number: 1.0 Start Date*: 2009-05-06
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie
    Full Title: Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia
    Medical condition: Grade 2/3 Cervical Intraepithelial Neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049701 Cervical intraepithelial neoplasia II LLT
    9.1 10049702 Cervical intraepithelial neoplasia III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005377-31 Sponsor Protocol Number: ISRCTN45751386 Start Date*: 2016-01-20
    Sponsor Name:HYKS Naistensairaala
    Full Title: Randomized trial of treatment and follow-up of vaginal intraepithelial neoplasia (VAIN)
    Medical condition: VAIN, vaginal intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046890 Vaginal cancer stage 0 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000746-59 Sponsor Protocol Number: ISRCTN23349576 Start Date*: 2016-02-18
    Sponsor Name:HYKS Naistensairaala
    Full Title: Randomized trial of treatment of vaginal intraepithelial neoplasia (VAIN).
    Medical condition: VAIN, vaginal intraepithelial neoplasia
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046890 Vaginal cancer stage 0 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023271-26 Sponsor Protocol Number: MI-CI-C02 Start Date*: 2011-02-01
    Sponsor Name:Mithra Pharmaceuticals SA
    Full Title: A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly appl...
    Medical condition: High Grade of Cervical Intraepithelial Neoplasia (CIN).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007494 Carcinoma uterine cervix in situ LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004604-31 Sponsor Protocol Number: PCCE201/08 Start Date*: 2008-10-28
    Sponsor Name:Photocure ASA
    Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia.
    Medical condition: Low grade cervical intraepithelial neoplasia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066238 Cervical low grade squamous intraepithelial lesion LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002035-26 Sponsor Protocol Number: 115411 Start Date*: 2011-10-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10033723 Papilloma viral infection NOS LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    14.0 10038604 - Reproductive system and breast disorders 10056576 Cervical intraepithelial neoplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023903-91 Sponsor Protocol Number: PCCE203/10 Start Date*: Information not available in EudraCT
    Sponsor Name:Photocure ASA
    Full Title: A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2).
    Medical condition: Patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10066238 Cervical low grade squamous intraepithelial lesion LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-001342-19 Sponsor Protocol Number: YHGT-CEV-R1 Start Date*: 2020-11-13
    Sponsor Name:Asieris MediTech Co., Ltd.
    Full Title: A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepit...
    Medical condition: Patients with cervical histologic HSIL.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004872 10064455 HSIL LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) SK (Completed) PL (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004933-14 Sponsor Protocol Number: V502-003-01 Start Date*: 2006-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002308-10 Sponsor Protocol Number: TOPIC-2 Start Date*: 2015-10-20
    Sponsor Name:
    Full Title: A randomized, single blinded trial to evaluate the efficacy of Imiquimod in women with residual/recurrent Cervical Intraepithelial Neoplasia (CIN) after previous treatment
    Medical condition: Residual or recurrent Cervical Intraepithelial Neoplasia (CIN)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001260-34 Sponsor Protocol Number: 414520 Start Date*: 2014-09-09
    Sponsor Name:Maastricht University Medical Center
    Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): a randomized controlled trial
    Medical condition: High grade cervical intraepithelial neoplasia.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002096-96 Sponsor Protocol Number: NL57849.068.16 Start Date*: 2016-09-20
    Sponsor Name:Maastricht University Medical Center
    Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia, a multicenter, open-label, non-randomized, controlled study (TOPIC-3 study)
    Medical condition: High-grade Cervical Intraepithelial Neoplasia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004518-32 Sponsor Protocol Number: ITIC2-2.3 Start Date*: 2013-02-13
    Sponsor Name:Medizinische Universität Wien
    Full Title: ITIC2 Trial - Topical Imiquimod versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial
    Medical condition: In this randomized controlled, multi-center trial we will investigate the non-inferiority of a topical IMQ treatment compared to surgical standard treatment in selected patients diagnosed with CIN ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002932-42 Sponsor Protocol Number: V501-110-01 Start Date*: 2016-12-14
    Sponsor Name:MSD K.K., a subsidiary of Merck & Co., Inc
    Full Title: A Phase IV Open-label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 ...
    Medical condition: Human Papillomavirus infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004114-17 Sponsor Protocol Number: HPV-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-1...
    Medical condition: HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    20.0 100000004872 10066237 Cervical high grade squamous intraepithelial lesion LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) EE (Completed) ES (Restarted) PL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004721-40 Sponsor Protocol Number: HPV-EU-001 Start Date*: 2015-04-22
    Sponsor Name:Genexine, Inc
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularl...
    Medical condition: Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), Grade 2/3 (CIN 2/3) or Grade 3 (CIN3)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038604 - Reproductive system and breast disorders 10008263 Cervical dysplasia PT
    Population Age: Adults Gender: Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011617-25 Sponsor Protocol Number: V503-002 Start Date*: 2009-10-16
    Sponsor Name:MSD Finland Oy
    Full Title: A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents an...
    Medical condition: Cervical Cancer
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-011357-41 Sponsor Protocol Number: 112772 Start Date*: 2009-07-01
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the fir...
    Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002945-10 Sponsor Protocol Number: V501-020 Start Date*: 2005-02-18
    Sponsor Name:Suomen MSD OY
    Full Title: A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the I...
    Medical condition: Prevention of Human Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    7.0 10063001 LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 12:41:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA